The detection of the ETV6-PAX5 fusion protein, for example, is associated with a poor prognosis and a higher risk of relapse, which may require more intensive therapy.[59] Furthermore, the detection of rearrangements in PAX5 provides a potential therapeutic target for the treatment of ALL. This evidence concerns the gene PAX5 and acute lymphoblastic leukemia.